Influenza A virus hemagglutinin (H1 subtype) and neuraminidase (N1 subtype) (HA (H1), NA (N1))

The **Influenza A H1N1 2009 viral antigens** primarily refer to the hemagglutinin (HA) and neuraminidase (NA) surface glycoproteins of the 2009 pandemic influenza A H1N1 virus. HA mediates viral attachment and fusion with host respiratory epithelial cells, while NA cleaves sialic acids to allow release of progeny virions. These antigens are the main targets of neutralizing antibodies and antiviral drugs, and are responsible for the virus’s capacity to evade immunity via antigenic drift. HA exhibits several major antigenic sites (Sa, Sb, Ca, Cb) prone to immune-driven evolution. Both HA and NA are strongly immunogenic and serve as key markers for the detection of infection, evaluation of vaccine efficacy, and selection of antiviral therapy. If further precision is needed (for example, for structured data fields), consider listing the antigens separately as "Hemagglutinin H1 of Influenza A virus" and "Neuraminidase N1 of Influenza A virus."

Other names

Swine-origin influenza A (H1N1) 2009 antigensPandemic H1N1 2009 antigensH1N1pdm09 HAH1N1pdm09 NANovel H1N1 viral antigensSwine flu H1N1 antigens

NA inhibitors block release of new virions by inhibiting neuraminidase. Neutralizing antibodies block HA-mediated host cell entry or trigger immune-mediated clearance. Universal vaccine candidates target conserved HA stem epitopes to induce broadly neutralizing responses.